诺和诺德Novo Nordisk (NVO) 2008年年度报告「NYSE」.pdf

1、Ph2 FSDOBGGSRRAOONECFLOOOORCNEWRCEEENSDCM*SNovo Nordisk A/S Annual Report 2008Financial,social and environmental performanceOur focus isour strengthPerformancehighlights2008 2008 2007 ChangeFinancial performanceSales total DKK million 45,553 41,831 9%Diabetes care DKK million 33,356 30,478 9%Of whic

2、h modern insulins DKK million 17,317 14,008 24%Biopharmaceuticals DKK million 12,197 11,353 7%Gross profi t DKK million 35,444 32,038 11%Gross margin%77.8 76.6Sales and distribution costs%of sales 28.2 29.6Research and development costs%of sales 17.2 20.4Research and development costs excl AERx*)%of

3、 sales 16.5 17.2Administration expenses%of sales 5.8 6.0Operating profi t DKK million 12,373 8,942 38%Operating profi t excl AERx*)DKK million 12,698 10,267 24%Net profi t DKK million 9,645 8,522 13%Effective tax rate%24.0 22.3Capital expenditure DKK million 1,754 2,268(23%)Free cash fl ow DKK milli

4、on 11,015 9,012 22%Long-term fi nancial targetsOperating profi t growth%38.4(1.9)Operating profi t growth excl AERx*)%23.7 12.6Operating margin%27.2 21.4Operating margin excl AERx*)%27.9 24.5Return on invested capital(ROIC)%37.4 27.2Cash to earnings(three-year average)%97.6 87.0Non-fi nancial perfor

5、manceEmployment impact worldwide Number of jobs 88,500 81,600 8%Water consumption 1,000 m3 2,684 3,231(17%)Recycling percentage(waste)%51 38CO2 emissions 1,000 tons 215 236(9%)Employees FTE 26,575 25,516 4%Employee turnover rate%12.1 11.6Engaging culture(employee engagement)Scale 15 4.2 4.1New paten

6、t families(fi rst fi ling)Number 71 116(39%)Share performanceDividend per share(proposed)DKK 6.00 4.50 33%Closing share price(B shares)DKK 271 335(19%)Market capitalisation(B shares)*)DKK billion 135 172(22%)*)Excluding non-recurring costs related to discontinuation of all pulmonary diabetes project